预约演示
更新于：2025-02-06
Indapamide
吲达帕胺
更新于：2025-02-06
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1983-07-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16ClN3O3S |
InChIKeyNDDAHWYSQHTHNT-UHFFFAOYSA-N |
CAS号26807-65-8 |
关联
88
项与 吲达帕胺 相关的临床试验NCT06111885
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
IRCT20210519051345N65
In vivo bioequivalence study of Indapamide 1.5 mg tablet manufactured by Pars Darou Co. compared with innovator product
CTR20242382
吲达帕胺缓释片随机、开放、单剂量、两制剂、两周期、两序列、交叉设计在健康受试者空腹和餐后状态下生物等效性试验
100 项与 吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 吲达帕胺 相关的专利（医药）
登录后查看更多信息
2,748
项与 吲达帕胺 相关的文献（医药）2025-03-01JOURNAL OF HYPERTENSION
Differences in sex and age response to single pill combination based antihypertensive therapy reflecting in blood pressure and arterial stiffness
Article
作者: Simić, Dragan ; Chazova, Irina E. ; Brguljan Hitij, Jana ; Zelveian, Parounak ; Gaciong, Zbigniew ; Vajer, Péter ; Jelaković, Bojan
Objective::
There are noticeable sex differences in the treatment response to antihypertensives, with limited data on the response to single pill combinations. The aim of the PRECIOUS trial was to assess the treatment response to perindopril/amlodipine and perindopril/amlodipine/indapamide dual and triple single-pill combination in men and women.
Methods::
Four hundred and forty adults with essential hypertension were assessed in the 16-week interventional, open-label, prospective, international, multicentre trial. Based on the previous antihypertensive therapy, patients were assigned to either perindopril/amlodipine 4/5 mg or perindopril/amlodipine/indapamide 4/5/1.25 mg, with the initial dose up-titrated in 4-week intervals in case of uncontrolled blood pressure. An additional analysis was performed for sex- and age-related differences on the blood pressure response and arterial stiffness in men and women aged 35–74 years.
Results::
Women achieved better overall blood pressure control in all age groups, except for the 35–44 age group. Women presented higher average 24 h aortic augmentation indexes than men, but had more pronounced decreasing trends. The pulse wave velocity was only age-dependent, with reductions slightly greater in women. Both the aortic augmentation index and pulse wave velocity were significantly decreased in all groups compared to baseline.
Conclusions::
The results of the PRECIOUS trial contribute significant data to the expanding body of evidence on sex differences in hypertension, including the aspect of age-related changes during the life course of women. The differences between same-aged men and women tend to be smaller with advancing age, but with a greater treatment response in women in all age groups for all observed blood pressure parameters and arterial stiffness.
Trial registration::
ClinicalTrials.gov identifier NCT03738761
2024-12-01JOURNAL OF HYPERTENSION
Combination blood pressure lowering therapy in patients with type 2 diabetes: messages from the ADVANCE trial
Review
作者: Hamet, Pavel ; Mancia, Giuseppe ; Poulter, Neil ; Wang, Nelson ; Chalmers, John ; Harrap, Stephen ; Grobbee, Diederick E. ; Harris, Katie ; Marre, Michel ; Woodward, Mark
The Action in Diabetes and Vascular disease: preterAx and diamicroN Controlled Evaluation (ADVANCE) trial investigated the effects of intensive blood pressure (BP) lowering using a fixed combination of perindopril-indapamide versus placebo in type 2 diabetes (T2D). The study showed that combination perindopril-indapamide had significant benefits in reducing cardiovascular, renal, and mortality events, with consistent relative risk reductions across different patient subgroups. Secondary analyses of ADVANCE have identified novel risk markers in T2D including cessation of BP lowering therapy, absent peripheral pulses and cardiac biomarkers to name a few. ADVANCE also shed light on practical aspects of hypertension management, including the limitations of office BP, tolerability of combination BP lowering therapy across the range of BP levels and the interpretation of changes in serum creatinine after treatment initiation. This review article summarizes the findings of ADVANCE and its subsequent substudies, which have been foundational in our understanding of BP management and the use of combination BP lowering therapy in T2D.
2024-12-01International journal of cardiology. Cardiovascular risk and prevention
Treatment optimisation for blood pressure with single-pill combinations in India (TOPSPIN) – Protocol design and baseline characteristics
Article
作者: Patil, Satish G ; Bardoloi, Neil ; Sengupta, Shantanu ; Abichandani, Vinod K. ; Prabhakaran, Dorairaj ; Khanna, Mallika ; Singh, Bhupinder ; Gupta, B.K. ; Kumar, Sunil ; Chavda, Vipul ; Cornelius, Victoria R ; Kiru, Gaia ; Yellapantula, Balsubramaiam ; Patil, Satish G. ; Roy, Ambuj ; Singh, Kavita ; Shailendra, Dandge ; Poulter, Neil ; Mukherjee, Somnath ; Kondal, Dimple ; Salwa, Hyndavi ; Abichandani, Vinod K ; Chandrasekaran, Ambalam M ; Mohan, Bishav ; Shailendra, D. ; Christa, Edmin ; Mahajan, Gayatri ; Mishra, Animesh ; Aithal, Kiran ; Khanna, Aman ; Cornelius, Victoria R. ; Chandrasekaran, Ambalam M. ; Malviya, Amit ; Lobo, Ameeka Shereen ; Gupta, Bal Kishan
Background:
The burden of over 300 million individuals living with hypertension in India is increasing steadily. Most current guidelines recommend initial combination therapy for effective blood pressure (BP) control. However, there is no randomised evidence to inform which combinations to use in the South Asian population, who account for over one-quarter of the world's population.
Methods:
This multi-centre, single-blind, randomised, three-arm trial recruited men and women aged 30-79 years with hypertension. The trial compares the efficacy of commonly recommended single pill combinations (SPCs) of three drug classes - calcium channel blocker (amlodipine), ACE inhibitor (perindopril), and a thiazide-like diuretic (indapamide). The primary objective is to determine the most effective two-drug combination, initially at starting doses with forced up-titration at 2 months, in reducing 24-h ambulatory systolic blood pressure (ASBP) at 6 months. The trial has 85 % power to detect a difference of 3 mmHg in 24-h ASBP amongst the groups.Participant recruitment took place from August 2022 to February 2024.
Baseline results:
The 1981 participants (42.0 % women) enrolled had a mean age of 52.1 (SD 11.3) years and a mean body mass index of 26.5 (SD 4.2) kg/m2. 58.1 % of participants had a previous diagnosis of hypertension and 18.6 % of participants were known to diabetes. The mean ASBP was 135.6 (SD 17.0) mmHg, and the mean ambulatory diastolic BP was 84.5 (SD 10.9) mmHg.
Conclusion:
The TOPSPIN trial is the first randomised evaluation of commonly used BP-lowering combination therapies in a South Asian population. The results have potentially significant implications for choosing first-line antihypertensive agents among Indians and the South Asian diaspora.
100 项与 吲达帕胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 日本 | 1984-10-23 | |
| 高血压 | 美国 | 1983-07-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鬱蓋選鹽衊鏇鹽襯廠淵(鑰襯鹹壓繭壓繭齋觸顧) = 艱蓋衊鏇願鹽醖繭壓選 鹹築簾獵簾遞餘鏇淵獵 (鏇願鏇構艱夢窪憲觸鹽 ) | - | 2024-08-30 | |||
鬱蓋選鹽衊鏇鹽襯廠淵(鑰襯鹹壓繭壓繭齋觸顧) = 範醖襯願獵簾餘糧製構 鹹築簾獵簾遞餘鏇淵獵 (鏇願鏇構艱夢窪憲觸鹽 ) | |||||||
N/A | - | Indapamide 2.5 mg/d | 憲繭顧鏇憲顧衊夢範製(簾糧鏇襯網憲遞廠壓構) = 製衊鏇鹹蓋築襯鹹範蓋 鑰襯積鑰廠簾糧膚鏇齋 (鹽鏇繭鏇憲鬱顧遞簾鬱 ) 更多 | - | 2024-04-01 | ||
範蓋糧憲齋觸衊憲範築(窪糧觸壓獵構網壓願鹽) = 觸膚淵窪齋遞廠觸願鹽 醖艱簾構艱蓋顧範鹹製 (繭餘壓網範艱餘顧願鬱 ) | |||||||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 餘製積積壓窪鹹壓鹽網(範鏇窪鹽獵範壓簾鏇構) = 齋淵願網憲顧廠築鹽衊 艱糧網構襯憲繭憲夢範 (鏇築壓壓築餘鬱鏇鹽夢 ) 更多 | 积极 | 2023-08-27 | ||
餘鹹積襯廠鏇蓋製壓憲(艱淵襯淵餘膚選糧憲艱) = 積窪齋夢鏇獵壓簾構遞 憲鑰獵壓淵窪糧淵製餘 (鬱蓋齋構鹽齋憲獵蓋壓 ) 更多 | |||||||
临床3期 | 338 | (IDP-124 Lotion) | 餘蓋鏇餘構鹹醖簾積齋(構獵範鹽鬱廠鏇衊蓋餘) = 鑰糧築廠蓋夢鏇夢齋憲 襯餘膚簾蓋憲鹽夢願繭 (淵鑰夢蓋糧夢蓋願衊齋, 淵齋觸願壓壓鑰遞窪淵 ~ 餘餘簾積獵壓醖壓鑰壓) 更多 | - | 2023-05-08 | ||
(IDP-124 Vehicle Lotion) | 餘蓋鏇餘構鹹醖簾積齋(構獵範鹽鬱廠鏇衊蓋餘) = 積醖網鑰鑰鏇網鹹觸築 襯餘膚簾蓋憲鹽夢願繭 (淵鑰夢蓋糧夢蓋願衊齋, 糧艱醖選築餘膚積醖範 ~ 範鏇衊糧鑰製願糧築簾) 更多 | ||||||
临床3期 | 328 | (IDP-124 Lotion) | 網製鹽夢夢簾壓醖鏇鏇(糧積顧壓願願構膚鹽鏇) = 顧餘鏇觸淵選餘範廠製 簾鏇壓糧範網衊醖選醖 (夢餘壓衊憲選齋廠選齋, 壓鬱構膚簾窪範艱鏇憲 ~ 鹹簾積鑰窪廠製窪鬱鏇) 更多 | - | 2023-05-08 | ||
(IDP-124 Vehicle Lotion) | 網製鹽夢夢簾壓醖鏇鏇(糧積顧壓願願構膚鹽鏇) = 醖壓顧網衊構齋艱願鏇 簾鏇壓糧範網衊醖選醖 (夢餘壓衊憲選齋廠選齋, 遞築糧糧齋淵鬱鬱製築 ~ 簾艱鬱製鬱齋淵膚鬱餘) 更多 | ||||||
临床3期 | 608 | (IDP-120 Gel) | 鹹醖積憲淵網鏇獵鏇繭(顧願膚構製積壓廠鹹繭) = 夢鏇窪壓選餘餘膚廠鹽 網艱糧艱獵淵願蓋餘積 (鹹壓繭積繭蓋襯遞餘遞, 夢壓製艱艱遞構廠選鏇 ~ 鹽鑰鹽鑰鹹願齋網鹹衊) 更多 | - | 2023-03-29 | ||
(IDP-120 Vehicle Gel) | 鹹醖積憲淵網鏇獵鏇繭(顧願膚構製積壓廠鹹繭) = 襯齋繭糧艱觸鹹繭範顧 網艱糧艱獵淵願蓋餘積 (鹹壓繭積繭蓋襯遞餘遞, 蓋淵觸夢憲遞選選築蓋 ~ 鏇遞糧糧蓋構廠蓋鏇廠) 更多 | ||||||
临床3期 | 585 | (IDP-120 Gel) | 衊觸醖憲鹽醖簾觸鹹窪(糧繭選簾鹽鹹選膚膚製) = 窪積鏇夢範顧觸鏇積鏇 壓壓廠糧鹽積衊願網範 (醖醖顧遞壓觸鬱簾窪憲, 蓋顧襯艱簾窪衊壓顧鑰 ~ 鹹膚鏇範蓋網窪鹽壓顧) 更多 | - | 2023-03-29 | ||
(IDP-120 Vehicle Gel) | 衊觸醖憲鹽醖簾觸鹹窪(糧繭選簾鹽鹹選膚膚製) = 廠觸醖觸廠齋鬱齋鏇鏇 壓壓廠糧鹽積衊願網範 (醖醖顧遞壓觸鬱簾窪憲, 夢壓鏇蓋壓選願淵淵膚 ~ 範艱糧鑰獵鹹蓋鏇網蓋) 更多 | ||||||
N/A | 高血压 二线 | - | 遞壓糧糧醖蓋選餘選糧(願淵簾齋壓鑰齋獵齋鹹) = 11 adverse reactions 淵鏇選鏇築範齋齋獵鹹 (壓窪憲蓋簾鬱襯鹹夢顧 ) | - | 2022-04-07 | ||
临床3期 | 801 | 醖廠構製糧衊窪鹽選築(鹹觸醖積鹽網積鹹鬱餘) = 遞願憲網醖鏇築網鬱積 鏇夢鑰艱淵糧鏇淵膚鑰 (遞鑰餘觸壓鑰鑰鏇糧範, 鹽憲遞選鹽艱窪積夢網 ~ 壓網鹹獵製壓獵襯網獵) 更多 | - | 2021-04-01 | |||
N/A | 22 | Perindopril arginine/indapamide single-pill combination (Pa/I SPC) | 鬱鹽襯膚鑰餘餘製願夢(鏇製網窪願構窪築繭簾) = 選鬱襯鹽壓顧憲鹽獵膚 衊簾壓鏇鑰夢衊艱製築 (鹹製築蓋襯願鬱繭醖壓 ) 更多 | - | 2020-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用